INSMED INC (INSM)
US4576693075 - Common Stock
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Noteworthy Thursday Option Activity: DAL, QS, INSM
Insmed Moves Up In Market Cap Rank, Passing Camden Property Trust
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Notable Monday Option Activity: INSM, MARA, ALGM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed To Present at November 2024 Investor Conferences
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Notable Thursday Option Activity: LPLA, INSM, BMY
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter...
Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
/PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Notable Friday Option Activity: INSM, ORA, BPMC
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Moves Up In Market Cap Rank, Passing Camden Property Trust
Meta Stock Leads 5 Names Near Buy Points As Market Bounces
The major indexes rose strongly Friday on Fed Chair Jerome Powell's speech.
Notable Friday Option Activity: DECK, TTWO, INSM
INSM Stock Earnings: Insmed Misses EPS, Beats Revenue for Q2 2024
INSM stock results show that Insmed missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...